- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Sotatercept, SOC
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 543
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PTSD
- Interventions
- psilocybin, Supportive Therapy, Prolonged Exposure Therapy
- Drug · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Leukemia, MDS, Myelofibrosis, Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
- Drug · Radiation · Other
- Lead sponsor
- Rafic Farah, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Coronavirus Disease 2019 (COVID-19) Pneumonia
- Interventions
- Lenzilumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Other Skin
- Interventions
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Geriatric Hip Fracture
- Interventions
- XR™ Recovery Supplement, XR Carbohydrate Loading Supplement
- Dietary Supplement
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
- Interventions
- Bosutinib, Dasatinib, Imatinib, Nilotinib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- VerifyNow, Verigene
- Device
- Lead sponsor
- LifeBridge Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Influenza A
- Interventions
- Pimodivir 600 mg, Placebo, SOC Treatment
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 13 Years to 85 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
- Conditions
- AIS
- Interventions
- NBP Softgel Capsules, Placebo
- Drug
- Lead sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Jacksonville, Florida • Des Moines, Iowa + 15 more
- Conditions
- Spinal Fusion
- Interventions
- Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft
- Device · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Medication Management
- Interventions
- Medication counseling
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 198 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Urinary Tract Infections
- Interventions
- Gentamicin, Standard of Care
- Drug
- Lead sponsor
- Mercy Health Ohio
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Youngstown, Ohio
- Conditions
- Moderate to Severe Opioid-use Disorder
- Interventions
- Transmucosal Buprenorphine, Extended-release Buprenorphine
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 785 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 28
- States / cities
- Garden Grove, California • Panorama City, California • San Diego, California + 21 more
- Conditions
- High Grade Glioma
- Interventions
- Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
- Procedure · Drug · Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Rectal Adenocarcinoma
- Interventions
- Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
- Other · Radiation · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Temple, Texas
- Conditions
- HPV Vaccines
- Interventions
- SMS Text Message
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 12 Years to 26 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 9 more
- Conditions
- Glioma, Glioblastoma Multiforme
- Interventions
- Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HIV Infections
- Interventions
- TERA Intervention (TERA), Standard of Care (SOC)
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
- Conditions
- Adult Spinal Deformity
- Interventions
- Tranexamic Acid (Cyklokapron)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri